MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

Strona główna・Stock List・AnaptysBio Inc

AnaptysBio Inc

Open

SectorHealthcare

67.86 -3.13

Buy Sell

Overview

Share price change

24h

Current

Min

67.21

Max

70.01

Key metrics
By Trading Economics
Income	35M 50M
Sales	32M 108M
Profit margin	45.833
Employees	104
EBITDA	29M 68M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+21.08% upside

Dividends
By Dow Jones
Next Earnings	1 maj 2026

Market Stats
By TradingEconomics
Market Cap	440M 2B
Previous open	70.99
Previous close	67.86

News Sentiment

By Acuity

40%

60%

119 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

19.25 / 21.135 Support & Resistance

AnaptysBio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 kwi 2026, 23:36 UTC

Acquisitions, Mergers, Takeovers

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14 kwi 2026, 23:24 UTC

Hot Stocks

Stocks to Watch: Gloo, Broadcom, GitLab

14 kwi 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14 kwi 2026, 21:32 UTC

Major Market Movers

GitLab Shares Rise on Expanded Google Cloud Collaboration

14 kwi 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14 kwi 2026, 23:34 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

14 kwi 2026, 22:54 UTC

Earnings

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14 kwi 2026, 22:54 UTC

Earnings

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14 kwi 2026, 22:54 UTC

Earnings

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14 kwi 2026, 22:54 UTC

Earnings

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14 kwi 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14 kwi 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14 kwi 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14 kwi 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14 kwi 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14 kwi 2026, 22:14 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14 kwi 2026, 22:13 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14 kwi 2026, 22:12 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14 kwi 2026, 22:12 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14 kwi 2026, 22:10 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14 kwi 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

14 kwi 2026, 20:33 UTC

Acquisitions, Mergers, Takeovers

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 kwi 2026, 20:32 UTC

Hot Stocks

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14 kwi 2026, 19:59 UTC

Acquisitions, Mergers, Takeovers

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 kwi 2026, 19:38 UTC

Earnings

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 kwi 2026, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14 kwi 2026, 19:21 UTC

Market Talk

Major News Events

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14 kwi 2026, 19:09 UTC

Acquisitions, Mergers, Takeovers

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14 kwi 2026, 18:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 kwi 2026, 18:30 UTC

Market Talk

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Peer Comparison

Price change

AnaptysBio Inc Forecast

Price Target

By TipRanks

21.08% upside

12 Months Forecast

Average 83.22 USD 21.08%

High 140 USD

Low 50 USD

Based on 10 Wall Street analysts offering 12 month price targets forAnaptysBio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to AnaptysBio Inc - Dist in the past 3 months.

Technical Score

By Trading Central

19.25 / 21.135Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

119 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.